1. China's biopharmaceutical job market is recovering from a funding-led downturn, with hiring for AI drug discovery, smart medical devices, and overseas expansion rising sharply in the first half of 2026. Openings related to AI-driven drug discovery rose 84.0% from a year earlier, positions tied to smart medical devices surged 113.1%, and jobs involving overseas expansion increased 10.0%, according to a report by Chinese recruitment platform Zhaopin. [para. 1][para. 2]
2. The recovery reflects broader improvement in the pharmaceutical industry. China's pharmaceutical manufacturing sector reported a 5.6% increase in industrial value-added output in the first half, with industry profits rising 4.2% to 177.32 billion yuan ($26.4 billion) and export value climbing 7.8% to 123.9 billion yuan. The number of job seekers applying to biopharmaceutical companies also rose 7.7% during the period. [para. 3][para. 4][para. 5]
3. AI drug discovery has become one of the industry's fastest-growing areas, with job postings containing terms such as "AIDD" growing 84.0% year over year. These roles use artificial-intelligence algorithms to identify drug targets, screen compounds, and optimize molecular candidates to shorten development timelines. The strongest pay goes to workers combining pharmaceutical, AI, and data-analysis skills: computer-aided drug-design positions offered average monthly salaries of 25,465 yuan, while bioinformatics engineers were offered 14,826 yuan. [para. 6][para. 7][para. 8][para. 9]
4. Demand is also growing for clinical-trial staff as more innovative drug candidates move into clinical development. China registered more than 5,000 drug clinical trials in 2025 for the first time, with new-drug trials increasing 18.0% from a year earlier. Clinical research associates, clinical trial coordinators, and pharmacovigilance professionals face significant talent shortages. CRAs generally require bachelor's degrees (85.6% of postings) and roughly three years of project-management experience, while coordinator roles are more often entry-level (63.6% require an associate degree or less). [para. 10][para. 11][para. 12]
5. Hiring for smart medical-device research and development is expanding even faster. Job postings mentioning "surgical robots," "brain-computer interfaces," or "wearable devices" rose 113.1% from a year earlier. Positions related to intelligent medical-device development offered average monthly salaries above 20,000 yuan, exceeding the 14,849 yuan average for medical-device R&D jobs overall. [para. 13][para. 14]
6. Biopharmaceutical companies are also adding staff to support overseas expansion, with job postings containing terms including "overseas expansion," "cross-border," "FDA," and "CE certification" increasing 10.0% in the first half. Employers are seeking candidates with foreign-language ability and expertise in international registration, regulatory compliance, and localized operations. Cross-border e-commerce operations roles offered average monthly salaries of 10,064 yuan (59.0% requiring only an associate degree or less), while overseas business-development jobs offered 16,326 yuan, with 83.5% requiring a bachelor's degree and particular value placed on FDA and EU CE certification experience. [para. 15][para. 16][para. 17][para. 18]
7. The hiring rebound has been supported by a more active market for innovative drugs. China's drug regulator approved 2,318 drug marketing applications in the first half, including 38 innovative medicines classified as globally novel. The total value of outbound licensing transactions for innovative Chinese drugs reached about $110 billion in the period — 80% of the full-year 2025 total, marking a record high for a first half. [para. 19][para. 20]
8. The makeup of the talent pool is changing as well. Frontier technology roles are increasingly attracting workers from outside the sector. Among applicants for computer-aided drug-design positions, artificial intelligence was the fourth-largest prior-industry source at 6.5%, after researchers (10.6%), bioinformatics engineers (7.9%), and algorithm engineers (6.9%). Medical-device R&D is also drawing workers from machinery, electronics, and software backgrounds. [para. 21][para. 22][para. 23]
9. Beijing and Shanghai remain the country's biggest centers for pharmaceutical R&D and clinical research demand. Beijing accounted for 13.3% of biopharmaceutical R&D openings, 13.4% of clinical-research and trial openings, and 15.5% of medical-device R&D openings — the highest shares nationally in each category. Shanghai's 8.6% share of clinical-research positions exceeded its 7.4% share of biopharmaceutical R&D openings, reflecting its concentration of contract research organizations. Shenzhen accounted for 7.5% of medical-device R&D openings, second only to Beijing, supported by companies including Mindray Bio-Medical Electronics and BGI Genomics. [para. 24][para. 25][para. 26]
AI generated, for reference only
Sign in with Google
Sign in with Facebook
Sign in with 财新